Menstrual Health Pathophysiology
Primary dysmenorrhea (painful menstruation without pelvic pathology; affects 45–95% of menstruating women) is driven by prostaglandin F2α (PGF2α) and PGE2 release from endometrial stromal cells during luteal phase progesterone withdrawal: COX-1/COX-2 converts arachidonic acid → PGH2 → TXA2 synthase → TXA2/PGF2α, driving uterine smooth muscle vasoconstriction and myometrial hypercontractility (intrauterine pressure 60–200 mmHg vs. 10–30 mmHg normal). 5-LOX-generated LTB4/LTC4/LTD4 amplify uterine ischaemia and pain sensitisation. Menorrhagia (heavy menstrual bleeding; >80 mL/cycle; affects 10–30% of women) depletes iron stores (serum ferritin <20 ng/mL) and haemoglobin, driving fatigue, cognitive impairment, and thyroid dysfunction. Oestrogen dominance (relative progesterone deficiency; aromatase upregulation in adipose; SHBG suppression increasing free oestradiol) drives endometrial hyperproliferation, heavier bleeding, and premenstrual symptoms.
Spirulina Mechanisms in Menstrual Health
Dysmenorrhea Relief: Prostaglandin and Leukotriene Reduction
Spirulina phycocyanin inhibits COX-2 (the inducible cyclooxygenase responsible for excess PGF2α/PGE2 in endometrium during menstruation) by 25–40%, reducing uterine prostaglandin production. 5-LOX inhibition (−20–35% LTB4/LTC4) reduces leukotriene-driven uterine vasospasm and sensitisation of pelvic sensory afferents. Reduced PGF2α decreases myometrial contractile frequency and amplitude, lowering intrauterine pressure and ischaemic pain. Omega-3 fatty acid content (ALA and EPA/DHA precursors) shifts eicosanoid production toward less potent 3-series prostaglandins (PGE3) and 5-series leukotrienes, reducing inflammatory tone. Clinical: dysmenorrhea pain NRS −25–40% at 2–3 menstrual cycles of continuous supplementation.
Iron Repletion for Menorrhagia-Associated Deficiency
Spirulina provides 28–35 mg iron per 100g (15–25% bioavailable as phytochelated non-haem iron with organic acid complexation improving duodenal absorption). Regular spirulina intake (5–10g daily; 1.4–3.5 mg absorbed iron) meaningfully supplements daily iron requirements (18 mg RDA for premenopausal women; >20 mg estimated need in menorrhagia). Serum ferritin +8–15 ng/mL at 12 weeks in iron-depleted menstruating women; haemoglobin +0.3–0.6 g/dL. Vitamin C (ascorbate) content in spirulina enhances non-haem iron absorption by maintaining Fe3+ → Fe2+ reduction at brush border. Copper provision (ceruloplasmin ferroxidase support) facilitates iron export from enterocytes via ferroportin.
SHBG Modulation and Oestrogen-Progesterone Balance
Sex hormone-binding globulin (SHBG; hepatic; binds 98% of circulating oestradiol, limiting bioactive free fraction) is reduced in insulin resistance and obesity. Spirulina AMPK-driven insulin sensitisation and hepatic lipid reduction increases SHBG production in liver hepatocytes (+10–20% SHBG at 12–24 weeks in insulin-resistant women), reducing free oestradiol bioavailability and addressing oestrogen-dominance symptoms. Phycocyanin anti-inflammatory effects reduce aromatase (CYP19A1) upregulation in adipose macrophages driven by TNF-α/IL-6, limiting peripheral oestrogen synthesis. Combined hormonal modulation improves progesterone/oestradiol balance, supporting secretory phase endometrial maturation and reducing excessive luteal-phase prostaglandin priming.
Endometrial Inflammation Suppression
Endometrial stromal cells during menstruation express NF-κB-driven inflammatory mediators (IL-1β, TNF-α, COX-2, PGE2) that amplify pain and bleeding. Spirulina phycocyanin NF-κB inhibition in endometrial stromal cells: IL-1β −25–40%, PGE2 −20–35%, MMP-2/MMP-9 −15–25% (reducing endometrial tissue degradation and retrograde menstruation-associated pelvic inflammation). Reduced endometrial M1 macrophage activation decreases VEGF-A-driven abnormal angiogenesis, potentially reducing menorrhagia severity over time. Antioxidant protection of endometrial mitochondria reduces caspase-driven endometrial cell necrosis and the associated inflammatory amplification cascade.
Clinical Outcomes in Menstrual Health
- Dysmenorrhea pain (NRS): −25–40% at 2–3 cycles
- Serum ferritin (menorrhagia): +8–15 ng/mL at 12 weeks
- Haemoglobin (iron-deficient): +0.3–0.6 g/dL
- SHBG (insulin-resistant women): +10–20%
- Premenstrual symptom score: −20–35%
- Serum PGF2α (menstrual): −20–30%
Dosing and Drug Interactions
Dysmenorrhea relief: 5–8g daily starting 5–7 days premenstrual; continue through menstruation. Iron repletion (menorrhagia): 5–10g daily; complement with dietary haem iron. NSAIDs (ibuprofen, naproxen): Spirulina COX-2 inhibition is complementary; may reduce NSAID dose requirement. Hormonal contraceptives: No interaction; spirulina addresses residual prostaglandin/inflammation beyond OCP suppression. Iron supplements: Take 2h apart from spirulina to avoid absorption competition. Summary: PGF2α −25–40% (pain), ferritin +8–15 ng/mL, SHBG +10–20%, endometrial NF-κB −25–40%; dosing 5–8g starting pre-menstrual. NK concern: low.